Midodrine in the Recovery Phase of Septic Shock

Midodrine Use in the Recovery Phase of Septic Shock

Status

Withdrawn

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02990546

Enrollment

Registered

2016-12-13

Start date

2017-03-01

Completion date

2018-05-02

Last updated

2024-01-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Septic Shock

Brief summary

The aim of this study is to investigate the role of oral midodrine in the recovery of septic shock. The investigators hypothesize that the oral drug can reduce central line days and ICU length of stay.

Detailed description

The investigators aim to investigate the use of midodrine in the recovery phase of septic shock in a randomized control trial. The investigators hypothesize that midodrine use initiated after stabilization or improving intravenous vasopressor requirement will lead to decreased length of ICU stay and length of time that intravenous vasopressors are required. The investigators plan to enroll and consent patients at the onset of septic shock. Once IV vasopressor requirement is stabilized or decreasing, males and females will be randomized in 1:1 fashion to receive either standard clinical care or standard clinical care plus oral midodrine. The investigators will analyze length of stay in the ICU, time on vasopressors, time needing a central line, and hospital length of stay.

Interventions

DRUGmidodrine

Midodrine will be given to treatment arm as enteral medication

OTHERStandard of Care

Patients in the control arm will receive standard of care for septic shock

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* • Patients aged 18-99 years old * Admitted to UVA medical ICU with diagnosis of septic shock.

Exclusion criteria

* Pregnant females, patients with childbearing potential will have urine pregnancy testing after consent * Patients \< 18 years * Prisoners * Patients already taking midodrine * Patients with cirrhosis and Child-Pugh Class C (Child-Pugh score \> 9)\_ * Patients with Increased intraocular pressure and glaucoma * Patients with allergy to midodrine * Non-English speaking patients * Patients without enteral access * Patients where the attending physician does not feel MAP goal of \> 65 mmHg is physiologically acceptable.

Design outcomes

Primary

Measure	Time frame	Description
ICU free days	28 days	ICU free days from first 28 days

Secondary

Measure	Time frame
Central venous catheter free days	28 days
IV vasopressor free days	28 days
Hospital length of stay	up to 90 days

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026